Micro Labs Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug
New Delhi: Micro Lab has got the green signal from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to manufacture and market the antidiabetic fixed-dose combination (FDC) Linagliptin 5mg/2.5mg/2.5 mg plus Dapagliflozin 10mg/10mg/5mg tablets
This came after the firm presented a Phase III clinical trial report of the FDC antidiabetic drug Linagliptin 5mg/2.5mg/2.5 mg plus Dapagliflozin 10mg/10 mg/5 mg tablets.
Linagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.
Linagliptin is a medicine used to treat type 2 diabetes. Type 2 diabetes is a condition where the body does not make enough insulin, or the insulin that it makes does not work properly. This can cause high blood sugar levels (hyperglycemia).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.